Baby Safety / Compounds / Fluralaner (Bravecto)

Is Fluralaner (Bravecto) safe for babies and kids?

Moderate risk for kids

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Fluralaner (Bravecto) poses heightened risk.

What is fluralaner (bravecto)?

The IUPAC name is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide.

Also known as: 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide, Fluralaner, Bravecto, AH252723.

IUPAC name
4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide
CAS number
864731-61-3
Molecular formula
C22H17Cl2F6N3O3
Molecular weight
556.3 g/mol
SMILES
CC1=C(C=CC(=C1)C2=NOC(C2)(C3=CC(=CC(=C3)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F
PubChem CID
25144319

Risk for babies

Moderate risk

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Fluralaner (Bravecto) poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Elevated risk

Fluralaner (Bravecto) poses pregnancy risk through potential teratogenicity, altered pharmacokinetics (increased blood volume, changed CYP activity), and placental transfer. FDA pregnancy category should be evaluated.

Suspected reproductive toxicant (GHS H361) or suspected endocrine disruptor. Precautionary approach warranted. Animal studies or limited human data suggest developmental toxicity potential.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

1 regulatory bodyhas classified Fluralaner (Bravecto).

AgencyYearClassificationNotes
IARC2022Not evaluated by IARC — fluralaner (Bravecto; MSD Animal Health/Merck Animal Health) is an FDA/CVM-approved isoxazoline ectoparasiticide for dogs and cats providing 12-week (dogs) or 8–12-week (cats) protection against fleas and ticks; FDA label carries a neurological adverse event warning (boxed warning or paragraph caution); no carcinogenicity classification

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter fluralaner (bravecto)

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Fluralaner (Bravecto):

  • Alternative drug class; Non-pharmacological therapy; Lowest effective dose
    Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.
    Relative cost: 1.2-2×

Frequently asked questions

Is fluralaner (bravecto) safe for kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Fluralaner (Bravecto) poses heightened risk.

What products contain fluralaner (bravecto)?

Fluralaner (Bravecto) appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to fluralaner (bravecto)?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

See Fluralaner (Bravecto) in the baby app

Look up products containing fluralaner (bravecto), compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (1)
  1. Fluralaner Bravecto MSD Animal Health FDA CVM; Isoxazoline GABA Chloride Channel Antagonist; 12-Week Duration Single Dose; FDA Neurological Adverse Event Warning 2018 2022 Tremors Ataxia Seizures; GABA-A Invertebrate Selectivity; Long Half-Life 12-15 Days Lipophilic Adipose; Bravecto Chewable Spot-On; Pharmacovigilance Post-Marketing; Aquatic Invertebrate Daphnia Ecotoxicity; IARC Not Evaluated (2022) — regulatory

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →